The Use of Next-Generation Sequencing in Treating Non-Squamous Non-Small-Cell Lung CancerVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Goeffrey Oxnard and Lauren Ritterhouse consider how next-generation sequencing (NGS) informs treatment of lung cancer patients in providing information on tumor mutational burden, microsatellite instability, unique targetable genomic signatures, as well as novel targets that may be best addressed in a clinical trial.
The publishers of Personalized Medicine in Oncology (PMO) invite you to watch an interview with Peter Hirth, PhD, Chief Executive Officer of Plexxikon. In part one, Dr. Hirth discusses the use of biomarkers, segmenting the population of melanoma patients into subsets, and other aspects of personalized medicine.
Matthew Palmgren presents the key issues that help justify the value and cost of personalized medicines